Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

BACKGROUND: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab are administered to colorectal cancer (CRC) patients who harbor wild-type RAS proto-oncogenes. However, a percentage of patients do not respond to this treatment. In addition to mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupini, Laura, Bassi, Cristian, Mlcochova, Jitka, Musa, Gentian, Russo, Marta, Vychytilova-Faltejskova, Petra, Svoboda, Marek, Sabbioni, Silvia, Nemecek, Radim, Slaby, Ondrej, Negrini, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624582/
https://www.ncbi.nlm.nih.gov/pubmed/26508446
http://dx.doi.org/10.1186/s12885-015-1752-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624582/
https://www.ncbi.nlm.nih.gov/pubmed/26508446
http://dx.doi.org/10.1186/s12885-015-1752-5

Ejemplares similares